These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33499047)

  • 21. BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells.
    Wu Z; Huang M; Gong Y; Lin C; Guo W
    Acta Biochim Biophys Sin (Shanghai); 2018 Apr; 50(4):355-361. PubMed ID: 29534162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of 2.4 nm thiolate-protected gold nanoparticles conjugated to Cetuximab for targeting glioblastoma cancer cells via the EGFR.
    Groysbeck N; Stoessel A; Donzeau M; da Silva EC; Lehmann M; Strub JM; Cianferani S; Dembélé K; Zuber G
    Nanotechnology; 2019 May; 30(18):184005. PubMed ID: 30650397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
    Musella V; Pietrantonio F; Di Buduo E; Iacovelli R; Martinetti A; Sottotetti E; Bossi I; Maggi C; Di Bartolomeo M; de Braud F; Daidone MG; Cappelletti V
    Int J Cancer; 2015 Sep; 137(6):1467-74. PubMed ID: 25704501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
    Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
    Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab.
    Kim N; Cho D; Kim H; Kim S; Cha YJ; Greulich H; Bass A; Cho HS; Cho J
    Int J Cancer; 2020 Apr; 146(8):2194-2200. PubMed ID: 31290142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The anticancer properties of iron core-gold shell nanoparticles in colorectal cancer cells.
    Wu YN; Wu PC; Yang LX; Ratinac KR; Thordarson P; Jahn KA; Chen DH; Shieh DB; Braet F
    Int J Nanomedicine; 2013; 8():3321-31. PubMed ID: 24039416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.
    Khelwatty SA; Essapen S; Seddon AM; Fan Z; Modjtahedi H
    Br J Cancer; 2015 Sep; 113(7):1010-9. PubMed ID: 26372697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxorubicin-loaded oligonucleotide conjugated gold nanoparticles: A promising in vivo drug delivery system for colorectal cancer therapy.
    Lee CS; Kim H; Yu J; Yu SH; Ban S; Oh S; Jeong D; Im J; Baek MJ; Kim TH
    Eur J Med Chem; 2017 Dec; 142():416-423. PubMed ID: 28870452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
    Zhang W; Gordon M; Lenz HJ
    Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles.
    Curley SA; Cherukuri P; Briggs K; Patra CR; Upton M; Dolson E; Mukherjee P
    J Exp Ther Oncol; 2008; 7(4):313-26. PubMed ID: 19227011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cetuximab in the treatment of patients with colorectal cancer.
    Garrett CR; Eng C
    Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
    Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
    Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gd
    Xiao L; Tian X; Harihar S; Li Q; Li L; Welch DR; Zhou A
    Spectrochim Acta A Mol Biomol Spectrosc; 2017 Jun; 181():218-225. PubMed ID: 28365452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
    Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
    Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
    Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
    Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Important factors for cell-membrane permeabilization by gold nanoparticles activated by nanosecond-laser irradiation.
    Yao C; Rudnitzki F; Hüttmann G; Zhang Z; Rahmanzadeh R
    Int J Nanomedicine; 2017; 12():5659-5672. PubMed ID: 28848345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer.
    Kubo A; Hashimoto H; Takahashi N; Yamada Y
    World J Gastroenterol; 2016 Jan; 22(2):887-94. PubMed ID: 26811634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model.
    Kao HW; Lin YY; Chen CC; Chi KH; Tien DC; Hsia CC; Lin MH; Wang HE
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3180-5. PubMed ID: 23628334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
    Gbenedio OM; Bonnans C; Grun D; Wang CY; Hatch AJ; Mahoney MR; Barras D; Matli M; Miao Y; Garcia KC; Tejpar S; Delorenzi M; Venook AP; Nixon AB; Warren RS; Roose JP; Depeille P
    JCI Insight; 2019 Jun; 5(15):. PubMed ID: 31237864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.